A citation-based method for searching scientific literature

Alka Bhatia, Yashwant Kumar. Expert Rev Clin Immunol 2014
Times Cited: 79







List of co-cited articles
613 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
12

Immune evasion in cancer: Mechanistic basis and therapeutic strategies.
Dass S Vinay, Elizabeth P Ryan, Graham Pawelec, Wamidh H Talib, John Stagg, Eyad Elkord, Terry Lichtor, William K Decker, Richard L Whelan, H M C Shantha Kumara,[...]. Semin Cancer Biol 2015
732
12

Cancer immunoediting: from immunosurveillance to tumor escape.
Gavin P Dunn, Allen T Bruce, Hiroaki Ikeda, Lloyd J Old, Robert D Schreiber. Nat Immunol 2002
10

The three Es of cancer immunoediting.
Gavin P Dunn, Lloyd J Old, Robert D Schreiber. Annu Rev Immunol 2004
10

Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
10

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.
Robert D Schreiber, Lloyd J Old, Mark J Smyth. Science 2011
10

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, Piotr Rutkowski, Jean-Jacques Grob, C Lance Cowey, Christopher D Lao, John Wagstaff, Dirk Schadendorf, Pier F Ferrucci,[...]. N Engl J Med 2017
8

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
Jesse M Zaretsky, Angel Garcia-Diaz, Daniel S Shin, Helena Escuin-Ordinas, Willy Hugo, Siwen Hu-Lieskovan, Davis Y Torrejon, Gabriel Abril-Rodriguez, Salemiz Sandoval, Lucas Barthly,[...]. N Engl J Med 2016
8

PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, Jennifer H Yearley, I Peter Shintaku, Emma J M Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu,[...]. Nature 2014
8

Mutational heterogeneity in cancer and the search for new cancer-associated genes.
Michael S Lawrence, Petar Stojanov, Paz Polak, Gregory V Kryukov, Kristian Cibulskis, Andrey Sivachenko, Scott L Carter, Chip Stewart, Craig H Mermel, Steven A Roberts,[...]. Nature 2013
7

Microenvironmental regulation of tumor progression and metastasis.
Daniela F Quail, Johanna A Joyce. Nat Med 2013
7

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Padmanee Sharma, Siwen Hu-Lieskovan, Jennifer A Wargo, Antoni Ribas. Cell 2017
7


Innate and adaptive immune cells in the tumor microenvironment.
Thomas F Gajewski, Hans Schreiber, Yang-Xin Fu. Nat Immunol 2013
6

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, Laura Q M Chow, Wen-Jen Hwu, Suzanne L Topalian, Patrick Hwu, Charles G Drake, Luis H Camacho, John Kauh, Kunle Odunsi,[...]. N Engl J Med 2012
6


Neoantigens in cancer immunotherapy.
Ton N Schumacher, Robert D Schreiber. Science 2015
6

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean Jacques Grob, C Lance Cowey, Christopher D Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski,[...]. N Engl J Med 2015
6

The immune contexture in human tumours: impact on clinical outcome.
Wolf Herman Fridman, Franck Pagès, Catherine Sautès-Fridman, Jérôme Galon. Nat Rev Cancer 2012
6


Posttranscriptional control of T cell effector function by aerobic glycolysis.
Chih-Hao Chang, Jonathan D Curtis, Leonard B Maggi, Brandon Faubert, Alejandro V Villarino, David O'Sullivan, Stanley Ching-Cheng Huang, Gerritje J W van der Windt, Julianna Blagih, Jing Qiu,[...]. Cell 2013
6

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
6

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins,[...]. N Engl J Med 2012
5

Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.
Héctor Peinado, Maša Alečković, Simon Lavotshkin, Irina Matei, Bruno Costa-Silva, Gema Moreno-Bueno, Marta Hergueta-Redondo, Caitlin Williams, Guillermo García-Santos, Cyrus Ghajar,[...]. Nat Med 2012
5

Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles.
Marina Colombo, Graça Raposo, Clotilde Théry. Annu Rev Cell Dev Biol 2014
5

Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation.
Irina Nazarenko, Sanyukta Rana, Alexandra Baumann, Jessica McAlear, Andrea Hellwig, Michael Trendelenburg, Günter Lochnit, Klaus T Preissner, Margot Zöller. Cancer Res 2010
436
5

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W Kantoff, Celestia S Higano, Neal D Shore, E Roy Berger, Eric J Small, David F Penson, Charles H Redfern, Anna C Ferrari, Robert Dreicer, Robert B Sims,[...]. N Engl J Med 2010
5

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Robert H I Andtbacka, Howard L Kaufman, Frances Collichio, Thomas Amatruda, Neil Senzer, Jason Chesney, Keith A Delman, Lynn E Spitler, Igor Puzanov, Sanjiv S Agarwala,[...]. J Clin Oncol 2015
5

Tumors as organs: complex tissues that interface with the entire organism.
Mikala Egeblad, Elizabeth S Nakasone, Zena Werb. Dev Cell 2010
748
5


Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
5

Immune escape mechanisms as a guide for cancer immunotherapy.
Gregory L Beatty, Whitney L Gladney. Clin Cancer Res 2015
530
5

Role of tumor microenvironment in tumorigenesis.
Maonan Wang, Jingzhou Zhao, Lishen Zhang, Fang Wei, Yu Lian, Yingfeng Wu, Zhaojian Gong, Shanshan Zhang, Jianda Zhou, Ke Cao,[...]. J Cancer 2017
657
5

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.
Hashem O Alsaab, Samaresh Sau, Rami Alzhrani, Katyayani Tatiparti, Ketki Bhise, Sushil K Kashaw, Arun K Iyer. Front Pharmacol 2017
824
5

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
5

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
Dirk Schadendorf, F Stephen Hodi, Caroline Robert, Jeffrey S Weber, Kim Margolin, Omid Hamid, Debra Patt, Tai-Tsang Chen, David M Berman, Jedd D Wolchok. J Clin Oncol 2015
5

Nivolumab plus ipilimumab in advanced melanoma.
Jedd D Wolchok, Harriet Kluger, Margaret K Callahan, Michael A Postow, Naiyer A Rizvi, Alexander M Lesokhin, Neil H Segal, Charlotte E Ariyan, Ruth-Ann Gordon, Kathleen Reed,[...]. N Engl J Med 2013
5

MAP kinase signalling pathways in cancer.
A S Dhillon, S Hagan, O Rath, W Kolch. Oncogene 2007
5

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Jacob Schachter, Antoni Ribas, Georgina V Long, Ana Arance, Jean-Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona McNeil, Michal Lotem,[...]. Lancet 2017
717
5

Cancer immunotherapy using checkpoint blockade.
Antoni Ribas, Jedd D Wolchok. Science 2018
5

Tumor-associated macrophages: from mechanisms to therapy.
Roy Noy, Jeffrey W Pollard. Immunity 2014
5

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.
Gang Chen, Alexander C Huang, Wei Zhang, Gao Zhang, Min Wu, Wei Xu, Zili Yu, Jiegang Yang, Beike Wang, Honghong Sun,[...]. Nature 2018
5


Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.
Jianjun Gao, Lewis Zhichang Shi, Hao Zhao, Jianfeng Chen, Liangwen Xiong, Qiuming He, Tenghui Chen, Jason Roszik, Chantale Bernatchez, Scott E Woodman,[...]. Cell 2016
692
5

Cancer immunotherapy comes of age.
Ira Mellman, George Coukos, Glenn Dranoff. Nature 2011
5

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.
Marta Łuksza, Nadeem Riaz, Vladimir Makarov, Vinod P Balachandran, Matthew D Hellmann, Alexander Solovyov, Naiyer A Rizvi, Taha Merghoub, Arnold J Levine, Timothy A Chan,[...]. Nature 2017
350
5

Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion.
Michael Platten, Wolfgang Wick, Benoît J Van den Eynde. Cancer Res 2012
450
5

CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer.
Bruno G Leclerc, Roxanne Charlebois, Guillaume Chouinard, Bertrand Allard, Sandra Pommey, Fred Saad, John Stagg. Clin Cancer Res 2016
127
5


Understanding the tumor immune microenvironment (TIME) for effective therapy.
Mikhail Binnewies, Edward W Roberts, Kelly Kersten, Vincent Chan, Douglas F Fearon, Miriam Merad, Lisa M Coussens, Dmitry I Gabrilovich, Suzanne Ostrand-Rosenberg, Catherine C Hedrick,[...]. Nat Med 2018
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.